SCHEMBL3255174

SCHEMBL3255174

CCOC(=O)c1c[nH]c2c(=O)[nH]c3ccc(S(=O)(=O)Nc4ccc(N5CCOCC5)cc4)cc3c12

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.57
MEN1 O00255 6/20 0.57
PDE3A Q14432 1/20 0.47
MAPT P10636 5/20 0.46
LMNA P02545 2/20 0.46
TP53 P04637 1/20 0.46
ALDH1A1 P00352 6/20 0.45
HPGD P15428 2/20 0.45
ALOX15 P16050 2/20 0.45
HSD17B10 Q99714 2/20 0.45
MAPK1 P28482 2/20 0.45
USP2 O75604 2/20 0.45
POLB P06746 5/20 0.45
TDP1 Q9NUW8 2/20 0.45
ALOX12 P18054 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
PABPC1 P11940 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3249274 0.88 PDE3A (0.52) KMT2AMEN1PDE3AMAPTLMNA
SCHEMBL3249910 0.88 KMT2A (0.51) KMT2AMEN1PDE3AMAPTLMNA
SCHEMBL3241955 0.87 MAPT (0.53) KMT2AMEN1MAPTLMNATP53
SCHEMBL3252031 0.86 PKM (0.53) KMT2AMEN1MAPTLMNATP53
SCHEMBL3251351 0.86 MEN1 (0.61) KMT2AMEN1MAPTLMNATP53
SCHEMBL3244722 0.85 PKM (0.56) KMT2AMEN1MAPTLMNATP53
SCHEMBL3249007 0.85 HSD17B10 (0.51) KMT2AMEN1MAPTLMNATP53
SCHEMBL3252629 0.85 HSD17B10 (0.51) KMT2AMEN1MAPTLMNATP53
SCHEMBL3254789 0.85 PKM (0.51) KMT2AMEN1PDE3AMAPTLMNA
SCHEMBL3250865 0.85 HSD17B10 (0.50) KMT2AMEN1MAPTLMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1899335-B1 PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS PF MEDICAMENT (FR) 2010-05-19 EP claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 KMT2A 1882/4885MEN1 3749/4885PDE3A 1334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.